The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders

Bibliography

• BALDWIN DS, ANDERSON IM, NUTT DJ et al.: Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British association for psychopharmacology. J. Psychopharmacol. (2005) 19(6):567-596.
   PubMed Web of Science ®Google Scholar
• HYTTEL J, BØGESØ KP, PERREGAARD J, SÁNCHEZ C: The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer. J. Neural. Transm. Gen. Sect. (1992) 88:157-160.
   PubMed Web of Science ®Google Scholar
• SANCHEZ C, BERGQVIST PB, BRENNUM LT et al.: Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities. Psychopharmacology (2003) 167(4):353-362.
   PubMed Web of Science ®Google Scholar
• BURKE WJ, KRATOCHVIL CJ: Stereoisomers in psychiatry: the case of escitalopram. Prim. Care Companion J. Clin. Psychiatry (2002) 4(1):20-24.
   PubMedGoogle Scholar
• THAYER A: Eli Lilly pulls the plug on Prozac isomer drug. Chem. Engin. News (2000) 78:8.
   Google Scholar
• OWENS MJ, KNIGHT DL, NEMEROFF CB: Second generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol. Psychiatry (2001) 50:345-350.
   PubMed Web of Science ®Google Scholar
• LUNDBERG J, CHRISTOPHERSEN JS, PETERSEN KB et al.: PET measurement of serotonin transporter occupancy: a comparison of escitalopram and citalopram. Int. J. Neuropharmacol. (2007) 4:1-9.
   Google Scholar
• MORK A, KREILGAARD M, SANCHEZ C: The R-enantiomer of citalopram counteracts escitalopram-induced increase in extracellular 5-HT in the frontal cortex of freely moving rats. Neuropharmacology (2003) 45(2):167-173.
   PubMed Web of Science ®Google Scholar
• SANCHEZ C, GRUCA P, PAPP M: R-Citalopram counteracts the antidepressant-like effect of escitalopram in a rat chronic mild stress model. Behav. Pharmacol. (2003) 14(5-6):465-470.
   PubMed Web of Science ®Google Scholar
• CHEN F, LARSEN MB, SANCHEZ C et al.: The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism: comparison with other serotonin transporter inhibitors. Eur. Neuropsychopharmacol. (2005) 15(2):193-198.
   PubMed Web of Science ®Google Scholar
• SANCHEZ C, BOGESO KP, EBERT B et al.: Escitalopram versus citalopram: the surprising role of the R-enantiomer. Psychopharmacology (2004) 174(2):163-176.
   PubMed Web of Science ®Google Scholar
• SANCHEZ C: R-citalopram attenuates anxiolytic effects of escitalopram in a rat ultrasonic vocalisation model. Eur. J. Pharmacol. (2003) 464(2-3):155-158.
   PubMed Web of Science ®Google Scholar
• STORUSTOVU S, SANCHEZ C, PORZGEN P et al.: R-citalopram functionally antagonises escitalopram in vivo and in vitro: evidence for kinetic interaction at the serotonin transporter. Br. J. Pharmacol. (2004) 142(1):172-180.
   PubMed Web of Science ®Google Scholar
• MNIE-FILALI O, MANSARI ME, ESPANA A et al.: Allosteric modulation of the effects of the 5-HT reuptake inhibitor escitalopram on the rat hippocampal synaptic plasticity. Neurosci. Lett. (2006) 395:23-27.
   PubMed Web of Science ®Google Scholar
• RAUSCH JL, CORLEY KM, HOBBY HM: Improved potency of escitalopram on the human serotonin transporter: demonstration of an ex vivo assay technique. J. Clin. Psychopharmacol. (2004) 24(2):209-213.
   PubMed Web of Science ®Google Scholar
• EL MANSARI M, SANCHEZ C, CHOUVET G et al.: Effects of acute and long-term administration of escitalopram and citalopram on serotonin neurotransmission: an in vivo electrophysiological study in the rat brain. Neuropsychopharmacology (2005) 30:1269-1277.
   PubMed Web of Science ®Google Scholar
• CEGLIA I, ACCONCIA S, FRACASSO C et al.: Effects of chronic treatment with escitalopram or citalopram on extracellular 5-HT in the prefrontal cortex of rats: role of 5-HT1A receptors. Br. J. Pharmacol. (2004) 142(3):469-478.
   PubMed Web of Science ®Google Scholar
• RAO N: The clinical pharmacokinetics of escitalopram. Clin. Pharmacokinet. (2007) 46(4):281-290.
   PubMed Web of Science ®Google Scholar
• SØGAARD B, MENGEL H, RAO N et al.: The pharmacokinetics of escitalopram after oral and intravenous administration of single and multiple doses to healthy subjects. J. Clin. Pharmacol. (2005) 45(12):1400-1406.
   PubMed Web of Science ®Google Scholar
• JOFFE P, LARSEN FS, PEDERSEN V et al.: Single-dose pharmacokinetics of citalopram in patients with moderate renal insufficiency or hepatic cirrhosis compared with healthy subjects. Eur. J. Clin. Pharmacol. (1998) 54(3):237-242.
   PubMed Web of Science ®Google Scholar
• VON MOLTKE LL, GREENBLATT DJ, GIANCARLO GM et al.: Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug Metab. Dispos. (2001) 29(8):1102-1109.
   PubMed Web of Science ®Google Scholar
• OLESEN OV, LINNET K: Studies on the stereoselective metabolism of citalopram by human liver microsomes and cDNA-expressed cytochrome P450 enzymes. Pharmacology (1999) 59(6):298-309.
   PubMed Web of Science ®Google Scholar
• CACCIA S: Metabolism of the newest antidepressants: comparison with related predecessors. IDrugs (2004) 7(2):143-150.
   PubMed Web of Science ®Google Scholar
• SIDHU J, PRISKORN M, POULSEN M et al.: Steady-state pharmacokinetics of the enantiomers of citalopram and its metabolites in humans. Chirality (1997) 9(7):686-692.
   PubMed Web of Science ®Google Scholar
• ROCHAT B, AMEY M, BAUMANN P: Analysis of enantiomers of citalopram and its demethylated metabolites in plasma of depressive patients using chiral reverse-phase liquid chromatography. Ther. Drug Monit. (1995) 17(3):273-279.
   PubMed Web of Science ®Google Scholar
• HEMERYCK A, DE VRIENDT C, BELPAIRE FM: Inhibition of CYP2C9 by selective serotonin reuptake inhibitors: in vitro studies with tolbutamide and (S)-warfarin using human liver microsomes. Eur. J. Clin. Pharmacol. (1999) 54(12):947-951.
   PubMed Web of Science ®Google Scholar
• LANE RM: Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors. Int. Clin. Psychopharmacol. (1996) 11(Suppl. 5):31-61.
   PubMed Web of Science ®Google Scholar
• HEMERYCK A, BELPAIRE FM: Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug–drug interactions: an update. Curr. Drug Metab. (2002) 3(1):13-37.
   PubMed Web of Science ®Google Scholar
• BROSEN K, SKJELBO E, RASMUSSEN BB et al.: Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem. Pharmacol. (1993) 45(6):1211-1214.
   PubMed Web of Science ®Google Scholar
• PRESKORN SH, GREENBLATT DJ, FLOCKHART D et al.: Comparison of duloxetine, escitalopram, and sertraline effects on cytochrome P450 2D6 function in healthy volunteers. J. Clin. Psychopharmacol. (2007) 27(1):28-34.
   PubMed Web of Science ®Google Scholar
• PRESKORN SH, ALDERMAN J, CHUNG M et al.: Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J. Clin. Psychopharmacol. (1994) 14:90-98.
   PubMed Web of Science ®Google Scholar
• GUTIERREZ MM, ROSENBERG J, ABRAMOWITZ W: An evaluation of the potential for pharmacokinetic interaction between escitalopram and the cytochrome P450 3A4 inhibitor ritonavir. Clin. Ther. (2003) 25(4):1200-1210.
   PubMed Web of Science ®Google Scholar
• MALLING D, POULSEN MN, SØGAARD B: The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects. Br. J. Clin. Pharmacol. (2005) 60(3):287-290.
   PubMed Web of Science ®Google Scholar
• STEINACHER L, VANDEL P, ZULLINO DF et al.: Carbamazepine augmentation in depressive patients non-responding to citalopram: a pharmacokinetic and clinical pilot study. Eur. Neuropsychopharmacol. (2002) 12(3):255-260.
   PubMed Web of Science ®Google Scholar
• MOLLER SE, LARSEN F, KHANT AZ et al.: Lack of effect of citalopram on the steady-state pharmacokinetics of carbamazepine in healthy male subjects. J. Clin. Psychopharmacol. (2001) 21(5):493-499.
   PubMed Web of Science ®Google Scholar
• AREBERG J, CHRISTOPHERSEN JS, POULSEN MN et al.: The pharmacokinetics of escitalopram in patients with hepatic impairment. AAPS J. (2006) 8(1):E14-E19.
   PubMed Web of Science ®Google Scholar
• RAMPONO J, HACKETT LP, KRISTENSEN JH et al.: Transfer of escitalopram and its metabolite demethylescitalopram into breastmilk. Br. J. Clin. Pharmacol. (2006) 62(3):316-322.
   PubMed Web of Science ®Google Scholar
• ARONSON S, DELGADO P: Escitalopram. Drugs Today (2004) 40(2):121-131.
   PubMed Web of Science ®Google Scholar
• BURKE WJ: Escitalopram. Expert Opin. Investig. Drugs (2002) 11(10):1477-1486.
   PubMed Web of Science ®Google Scholar
• DHILLON S, SCOTT LJ, PLOSKER GL: Escitalopram: a review of its use in the management of anxiety disorders. CNS Drugs (2006) 20(9):763-790.
   PubMed Web of Science ®Google Scholar
• KORAN LM, ABOUJAOUDE EN, GAMEL NN: Escitalopram treatment of kleptomania: an open-label trial followed by double-blind discontinuation. J. Clin. Psychiatry (2007) 68(3):422-427.
   PubMed Web of Science ®Google Scholar
• MURDOCH D, KEAM SJ: Escitalopram: a review of its use in the management of major depressive disorder. Drugs (2005) 65(16):2379-2404.
   PubMed Web of Science ®Google Scholar
• MONTGOMERY SA, LOFT H, SANCHEZ C et al.: Escitalopram (S-enantiomer of citalopram): clinical efficacy and onset of action predicted from a rat model. Pharmacol. Toxicol. (2001) 88:282-286.
   PubMedGoogle Scholar
• WADE A, MICHAEL LEMMING O, BANG HEDEGAARD K: Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int. Clin. Psychopharmacol. (2002) 17:95-102.
   PubMed Web of Science ®Google Scholar
• BURKE WJ, GERGEL I, BOSE A: Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J. Clin. Psychiatry (2002) 63(4):331-336.
   PubMed Web of Science ®Google Scholar
• GORMAN JM, KOROTZER A, SU G: Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials. CNS Spectrums (2002) 7:40-44.
   PubMed Web of Science ®Google Scholar
• LEPOLA UM, LOFT H, REINES EH: Escitalopram (10 – 20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int. Clin. Psychopharmacol. (2003) 18(4):211-217.
   PubMed Web of Science ®Google Scholar
• MONTGOMERY SA, HUUSOM AK, BOTHMER J: A randomized study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology (2004) 50:57-64.
   PubMed Web of Science ®Google Scholar
• BIELSKY RJ, VENTURA D, CHANG CC: A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J. Clin. Psychiatry (2004) 65:1190-1196.
   PubMed Web of Science ®Google Scholar
• MOORE N, VERDOUX H, FANTINO B: Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int. Clin. Psychopharmacol. (2005) 20:131-137.
   PubMed Web of Science ®Google Scholar
• LAM RW, ANDERSEN HF: The influence of baseline severity on efficacy of escitalopram and citalopram in the treatment of major depressive disorder: an extended analysis. Pharmacopsychiatry (2006) 39:180-184.
   PubMed Web of Science ®Google Scholar
• KENNEDY SH, ANDERSEN HF, LAM R: Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. J. Psychiatry Neurosci. (2006) 31:122-131.
   PubMed Web of Science ®Google Scholar
• KASPER S, SPADONE C, VERPILLAT P, ANGST J: Onset of action of escitalopram compared with other antidepressants: results of a pooled analysis. Int. Clin. Psychopharmacol. (2006) 21(2):105-110.
   PubMed Web of Science ®Google Scholar
• BOULENGER JP, HUUSOM AKT, FLOREA I et al.: A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients. Curr. Med. Res. Opin. (2006) 22:1331-1341.
   PubMed Web of Science ®Google Scholar
• WADE AG, GEMBERT K, FLOREA I: A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder. Curr. Med. Res. Opin. (2007) 23:1605-1614.
   PubMed Web of Science ®Google Scholar
• OLIE JP, TONNOIR B, MÉNARD F, GALINOWSKI A: A prospective study of escitalopram in the treatment of major depressive episodes in the presence or absence of anxiety. Depress Anxiety (2006) 24:318-324.
   Web of Science ®Google Scholar
• BANDELOW B, ANDERSEN HF, DOLBERG OT: Escitalopram in the treatment of anxiety symptoms associated with depression. Depress Anxiety (2007) 24:53-61.
   PubMed Web of Science ®Google Scholar
• ROY-BYRNE PP, CRASKE MG, STEIN MB: Panic disorder. Lancet (2006) 368(9540):1023-1032.
   PubMed Web of Science ®Google Scholar
• STAHL SM, GERGEL I, LI D: Escitalopram in the treatment of panic disorder: a randomized double-blind placebo controlled trial. J. Clin. Psychiatry (2003) 64:1322-1327.
   PubMed Web of Science ®Google Scholar
• LIEB R, BECKER E, ALTAMURA C: The epidemiology of generalized anxiety disorder in Europe. Eur. Neuropsychopharmacol. (2005) 15(4):445-452.
   PubMed Web of Science ®Google Scholar
• NINAN PT: Dissolving the burden of generalized anxiety disorder. J. Clin. Psychiatry (2001) 62(Suppl. 19):5-10.
   PubMed Web of Science ®Google Scholar
• ALLGULANDER C, BANDELOW B, HOLLANDER E et al.: World council of anxiety. WCA recommendations for the long-term treatment of generalized anxiety disorder. CNS Spectr. (2003) 8(S1):53-61.
   PubMed Web of Science ®Google Scholar
• DAVIDSON JR, BOSE A, KOROTZER A et al.: Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo-controlled, flexible dose study. Depress Anxiety (2004) 19:234-240.
   PubMed Web of Science ®Google Scholar
• BIELSKI RJ, BOSE A, CHANG CC: A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder. Ann. Clin. Psychiatry (2005) 17(2):65-69.
   PubMedGoogle Scholar
• DAVIDSON JR, BOSE A, WANG Q: Safety and efficacy of escitalopram in the long-term treatment of generalized anxiety disorder. J. Clin. Psychiatry (2005) 66(11):1441-1446.
   PubMed Web of Science ®Google Scholar
• BALDWIN DS, HUUSOM AKR, MAEHLUM E: Escitalopram and paroxetine in the treatment of generalised anxiety disorder: randomised, placebo-controlled, double-blind study. Br. J. Psychiatry (2006) 189(3):264-272.
   PubMed Web of Science ®Google Scholar
• GOODMAN WK, BOSE A, WANG Q: Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials. J. Affect. Disord. (2005) 87(2-3):161-167.
   PubMed Web of Science ®Google Scholar
• STEIN DJ, ANDERSEN HF, GOODMAN WK: Escitalopram for the treatment of GAD: efficacy across different subgroups and outcomes. Ann. Clin. Psychiatry (2005) 17(2):71-75.
   PubMedGoogle Scholar
• ALLGULANDER C, FLOREA I, HUUSOM AKT: Prevention of relapse in generalised anxiety disorder by escitalopram treatment. Int. J. Neuropsychopharmacol. (2006) 9:495-505.
   PubMed Web of Science ®Google Scholar
• FEHM L, PELISSOLO A, FURMARK T et al.: Size and burden of social phobia in Europe. Eur. Neuropsychopharmacol. (2005) 15(4):453-462.
   PubMed Web of Science ®Google Scholar
• AMERICAN PSYCHIATRIC ASSOCIATION: Practice guidelines for the treatment of psychiatric disorders. American Psychiatric Association, Arlington, Virginia, USA (2006).
   Google Scholar
• LADER M, STENDER K, BURGER V et al.: Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomized, double-blind, placebo controlled fixed dose study. Depress Anxiety (2004) 19:241-248.
   PubMed Web of Science ®Google Scholar
• KASPER S, STEIN DJ, LOFT H, NIL R: Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study. Br. J. Psychiatry (2005) 186:222-226.
   PubMed Web of Science ®Google Scholar
• MONTGOMERY SA, NIL R, DURR-PAL N et al.: A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. J. Clin. Psychiatry (2005) 66:1270-1278.
   PubMed Web of Science ®Google Scholar
• DELL'OSSO B, ALTAMURA AC, MUNDO E et al.: Diagnosis and treatment of obsessive–compulsive disorder and related disorders. Int. J. Clin. Pract. (2007) 61(1):98-104.
   PubMed Web of Science ®Google Scholar
• STEIN DJ, ANDERSEN EW, TONNOIR B, FINEBERG N: Escitalopram in obsessive–compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study. Curr. Med. Res. Opin. (2007) 23(4):701-711.
   PubMed Web of Science ®Google Scholar
• FINEBERG NA, LEMMING O, TONNOIR B et al.: Escitalopram in relapse prevention in patients with obsessive–compulsive disorder. Eur. Neuropsychopharmacol. (2007) 17(6-7):430-439.
   PubMed Web of Science ®Google Scholar
• GALVAO-DE ALMEIDA A, QUARANTINI LC, GOIS CR et al.: Obsessive–compulsive disorder: an open-label pilot trial of escitalopram. CNS Spectr. (2007) 12(7):519-524.
   PubMed Web of Science ®Google Scholar
• WAUGH J, GOA KL: Escitalopram. A review of its use in the management of major depressive and anxiety disorders. CNS Drugs (2003) 17(5):343-362.
   PubMed Web of Science ®Google Scholar
• MOLLER HJ, LANGER S, SCHMAUSS M: Escitalopram in clinical practice: results of an open-label trial in outpatients with depression in a naturalistic setting in Germany. Pharmacopsychiatry (2007) 40(2):53-57.
   PubMed Web of Science ®Google Scholar
• MUNDO E, BELLODI L, SMERALDI E: Effects of acute intravenous clomipramine on obsessive–compulsive symptoms and response to chronic treatment. Biol. Psychiatry (1995) 38:525-531.
   PubMed Web of Science ®Google Scholar
• MUNDO E, BAREGGI SR, PIROLA R et al.: Effect of acute intravenous clomipramine and antiobsessional response to proserotonergic drugs: is gender a predictive variable? Biol. Psychiatry (1999) 45(3):290-294.
   PubMed Web of Science ®Google Scholar
• BALDWIN DS, MONTGOMERY SA, NIL R, LADER M: Discontinuation symptoms in depression and anxiety disorders. Int. J. Neuropsychopharmacol (2007) 10:73-84.
   PubMed Web of Science ®Google Scholar
• LLORCA PM, FERNANDEZ JL: Escitalopram in the treatment of major depressive disorder: clinical efficacy, tolerability and cost-effectiveness vs venlafaxine extended release formulation. Int. J. Clin. Pract. (2007) 61(4):702-710.
   PubMed Web of Science ®Google Scholar
• ROBERT S, HAMNER MB, ULMER HG et al.: Open-label trial of escitalopram in the treatment of posttraumatic stress disorder. J. Clin. Psychiatry (2006) 67(10):1522-1526.
   PubMed Web of Science ®Google Scholar
• GRANT JE, POTENZA MN: Escitalopram treatment of pathological gambling with co-occurrent anxiety: an open-label pilot study with double-blind discontinuation. Int. Clin. Psychopharmacol. (2006) 21(4):203-209.
   PubMed Web of Science ®Google Scholar
• GADDE KM, RYAN WAGNER H, CONNOR KM et al.: Escitalopram treatment of trichotillomania. Int. Clin. Psychopharmacol. (2007) 22(1):39-42.
   PubMed Web of Science ®Google Scholar
• KORAN LM, ABOUJAOUDE EN, SOLVASON B et al.: Escitalopram for compulsive buying disorder: a double-blind discontinuation study. J. Clin. Psychopharmacol. (2007) 27:225-227.
   PubMed Web of Science ®Google Scholar
• DELL'OSSO B, ALTAMURA AC, HADLEY SJ et al.: An open label trial of escitalopram in the treatment of compulsive–impulsive Internet usage disorder. Eur. Neuropsychopharmacol. (2006) 16(S1):82-83.
   Google Scholar
• BAREGGI SR, BIANCHI L, CAVALLARO R et al.: Citalopram concentrations and response in obsessive–compulsive disorder. Preliminary results. CNS Drugs (2004) 18:329-335.
   PubMed Web of Science ®Google Scholar
• BAUMANN P, HIEMKE C, ULRICH S et al.: The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry (2004) 37:243-265.
   PubMed Web of Science ®Google Scholar
• JORGENSEN TR, STEIN DJ, DESPIEGEL N et al.: Cost-effectiveness analysis of escitalopram compared with paroxetine in treatment of generalized anxiety disorder in the United Kingdom. Ann. Pharmacother. (2006) 40:1752-1758.
   PubMed Web of Science ®Google Scholar
• CROOM KF, PLOSKER GL: Escitalopram: a pharmacoeconomic review of its use in depression. Pharmacoeconomics (2003) 21:1185-1209.
   PubMed Web of Science ®Google Scholar